TransMedics Group Quarterly Income Statements Chart
Quarterly
|
Annual
TransMedics Group Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-28 | 2019-09-28 | 2019-06-29 | 2019-03-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue: | ||||||||||||||||||||||||||
| net product revenue | 96,100,000 | 88,234,000 | 74,948,000 | 65,861,000 | 71,732,000 | 61,325,000 | 51,874,000 | 47,740,000 | 42,462,000 | 33,993,000 | ||||||||||||||||
| service revenue | 61,270,000 | 55,303,000 | 46,676,000 | 42,900,000 | 42,573,000 | 35,525,000 | 29,300,000 | 18,690,000 | 10,003,000 | 7,561,000 | ||||||||||||||||
| total revenue | 157,370,000 | 143,537,000 | 121,624,000 | 108,761,000 | 114,305,000 | 96,850,000 | 81,174,000 | 66,430,000 | 52,465,000 | 41,554,000 | 31,375,000 | 25,683,000 | 20,521,000 | 15,880,000 | 9,668,000 | 5,370,000 | 8,171,000 | 7,053,000 | 7,627,000 | 7,091,000 | 3,391,000 | 7,530,000 | 6,057,000 | 7,205,000 | 5,666,000 | 4,676,000 |
| yoy | 37.68% | 48.21% | 49.83% | 63.72% | 117.87% | 133.07% | 158.72% | 158.65% | 155.66% | 161.68% | 224.52% | 378.27% | 151.14% | 125.15% | 26.76% | -24.27% | 140.96% | -6.33% | 25.92% | -1.58% | -40.15% | 61.04% | ||||
| qoq | 9.64% | 18.02% | 11.83% | -4.85% | 18.02% | 19.31% | 22.19% | 26.62% | 26.26% | 32.44% | 22.16% | 25.15% | 29.23% | 64.25% | 80.04% | -34.28% | 15.85% | -7.53% | 7.56% | 109.11% | -54.97% | 24.32% | -15.93% | 27.16% | 21.17% | |
| cost of revenue: | ||||||||||||||||||||||||||
| cost of net product revenue | 19,421,000 | 16,312,000 | 16,545,000 | 13,246,000 | 14,470,000 | 14,084,000 | 14,065,000 | 11,086,000 | 8,558,000 | 7,306,000 | ||||||||||||||||
| cost of service revenue | 41,360,000 | 38,997,000 | 33,066,000 | 34,670,000 | 30,574,000 | 22,804,000 | 19,185,000 | 14,682,000 | 7,166,000 | 5,482,000 | ||||||||||||||||
| total cost of revenue | 60,781,000 | 55,309,000 | 49,611,000 | 47,916,000 | 45,044,000 | 36,888,000 | 33,250,000 | 25,768,000 | 15,724,000 | 12,788,000 | 10,672,000 | 7,568,000 | 6,171,000 | 3,776,000 | 2,682,000 | 1,597,000 | 2,582,000 | 2,242,000 | 2,799,000 | 2,053,000 | 1,482,000 | 2,670,000 | 2,316,000 | 2,989,000 | 2,333,000 | 2,103,000 |
| gross profit | 96,589,000 | 88,228,000 | 72,013,000 | 60,845,000 | 69,261,000 | 59,962,000 | 47,924,000 | 40,662,000 | 36,741,000 | 28,766,000 | 20,703,000 | 18,115,000 | 14,350,000 | 12,104,000 | 6,986,000 | 3,773,000 | 5,589,000 | 4,811,000 | 4,828,000 | 5,038,000 | 1,909,000 | 4,860,000 | 3,741,000 | 4,216,000 | 3,333,000 | 2,573,000 |
| yoy | 39.46% | 47.14% | 50.27% | 49.64% | 88.51% | 108.45% | 131.48% | 124.47% | 156.03% | 137.66% | 196.35% | 380.12% | 156.75% | 151.59% | 44.70% | -25.11% | 192.77% | -1.01% | 29.06% | 19.50% | -42.72% | 88.88% | ||||
| qoq | 9.48% | 22.52% | 18.35% | -12.15% | 15.51% | 25.12% | 17.86% | 10.67% | 27.72% | 38.95% | 14.29% | 26.24% | 18.56% | 73.26% | 85.16% | -32.49% | 16.17% | -0.35% | -4.17% | 163.91% | -60.72% | 29.91% | -11.27% | 26.49% | 29.54% | |
| gross margin % | 61.38% | 61.47% | 59.21% | 55.94% | 60.59% | 61.91% | 59.04% | 61.21% | 70.03% | 69.23% | 65.99% | 70.53% | 69.93% | 76.22% | 72.26% | 70.26% | 68.40% | 68.21% | 63.30% | 71.05% | 56.30% | 64.54% | 61.76% | 58.51% | 58.82% | 55.03% |
| operating expenses: | ||||||||||||||||||||||||||
| research, development and clinical trials | 15,934,000 | 17,160,000 | 16,464,000 | 14,266,000 | 13,858,000 | 11,380,000 | 10,761,000 | 11,132,000 | 8,291,000 | 5,871,000 | 5,756,000 | 6,808,000 | 6,714,000 | 7,534,000 | 6,314,000 | 5,163,000 | 6,295,000 | 4,532,000 | 4,548,000 | 4,155,000 | 3,903,000 | 6,225,000 | 6,262,000 | 4,939,000 | 4,787,000 | 3,882,000 |
| selling, general and administrative | 44,088,000 | 43,625,000 | 46,905,000 | 42,656,000 | 42,895,000 | 36,161,000 | 34,560,000 | 30,653,000 | 29,356,000 | 24,984,000 | 21,726,000 | 16,851,000 | 17,381,000 | 13,939,000 | 12,000,000 | 10,335,000 | 9,162,000 | 6,786,000 | 6,176,000 | 5,493,000 | 5,867,000 | 6,652,000 | 6,173,000 | 6,519,000 | 6,251,000 | 4,653,000 |
| total operating expenses | 60,022,000 | 60,785,000 | 63,369,000 | 56,922,000 | 56,753,000 | 47,541,000 | 45,321,000 | 68,997,000 | 37,647,000 | 30,855,000 | 27,482,000 | 23,659,000 | 24,095,000 | 21,473,000 | 18,314,000 | 15,498,000 | 15,457,000 | 11,318,000 | 10,724,000 | 9,648,000 | 9,770,000 | 12,877,000 | 12,435,000 | 11,458,000 | 11,038,000 | 8,535,000 |
| income from operations | 36,567,000 | 27,443,000 | 8,644,000 | 3,923,000 | 12,508,000 | 12,421,000 | 2,603,000 | -28,335,000 | -906,000 | -2,089,000 | -6,779,000 | -5,544,000 | -9,745,000 | -9,369,000 | -11,328,000 | -11,725,000 | -9,868,000 | -6,507,000 | -5,896,000 | -4,610,000 | -7,861,000 | -8,017,000 | -8,694,000 | -7,242,000 | -7,705,000 | -5,962,000 |
| yoy | 192.35% | 120.94% | 232.08% | -113.85% | -1480.57% | -694.59% | -138.40% | 411.09% | -90.70% | -77.70% | -40.16% | -52.72% | -1.25% | 43.98% | 92.13% | 154.34% | 25.53% | -18.83% | -32.18% | -36.34% | 2.02% | 34.47% | ||||
| qoq | 33.25% | 217.48% | 120.34% | -68.64% | 0.70% | 377.18% | -109.19% | 3027.48% | -56.63% | -69.18% | 22.28% | -43.11% | 4.01% | -17.29% | -3.39% | 18.82% | 51.65% | 10.36% | 27.90% | -41.36% | -1.95% | -7.79% | 20.05% | -6.01% | 29.24% | |
| operating margin % | 23.24% | 19.12% | 7.11% | 3.61% | 10.94% | 12.82% | 3.21% | -42.65% | -1.73% | -5.03% | -21.61% | -21.59% | -47.49% | -59.00% | -117.17% | -218.34% | -120.77% | -92.26% | -77.30% | -65.01% | -231.82% | -106.47% | -143.54% | -100.51% | -135.99% | -127.50% |
| other income: | ||||||||||||||||||||||||||
| interest expense | -3,476,000 | -3,461,000 | -3,571,000 | -3,617,000 | -3,623,000 | -3,598,000 | -3,605,000 | -3,590,000 | -2,505,000 | -1,091,000 | -1,007,000 | -787,000 | -972,000 | -960,000 | -978,000 | -979,000 | -965,000 | -952,000 | -971,000 | -971,000 | -1,001,000 | -1,042,000 | -1,063,000 | -1,084,000 | -1,113,000 | -1,093,000 |
| interest income and other income | 3,091,000 | 2,694,000 | 1,916,000 | 3,939,000 | 3,268,000 | 3,570,000 | ||||||||||||||||||||
| total other income | -385,000 | -767,000 | -1,655,000 | 322,000 | -355,000 | -28,000 | 1,260,000 | 1,406,000 | -74,000 | -536,000 | 78,000 | -1,863,000 | -1,756,000 | -1,187,000 | -1,323,000 | -1,228,000 | -794,000 | -1,406,000 | -405,000 | -472,000 | -630,000 | -825,000 | -473,000 | -1,028,000 | -1,480,000 | -923,000 |
| income before income taxes | 36,182,000 | 26,676,000 | 6,989,000 | 4,245,000 | 12,153,000 | 12,393,000 | 3,863,000 | -26,929,000 | -980,000 | -2,625,000 | -6,701,000 | -7,407,000 | -11,501,000 | -10,556,000 | -12,651,000 | -12,953,000 | -10,662,000 | -7,913,000 | -6,301,000 | -5,082,000 | -8,491,000 | -8,842,000 | -9,167,000 | -8,270,000 | -9,185,000 | -6,885,000 |
| benefit for income taxes | -1,275,000 | -994,000 | -132,000 | -29,000 | 41,000 | -196,000 | 168,000 | 1,507,000 | -21,000 | -11,000 | -19,000 | -19,000 | -22,000 | -6,000 | -17,000 | -9,000 | -6,000 | -4,000 | -10,000 | -6,000 | -6,000 | -10,000 | -10,000 | -10,000 | -10,000 | -10,000 |
| net income | 34,907,000 | 25,682,000 | 6,857,000 | 4,216,000 | 12,194,000 | 12,197,000 | 4,031,000 | -25,422,000 | -1,001,000 | -2,636,000 | -6,720,000 | -7,426,000 | -11,523,000 | -10,562,000 | -12,668,000 | -12,962,000 | -10,668,000 | -7,917,000 | -6,311,000 | -5,088,000 | -8,497,000 | -8,852,000 | -9,177,000 | -8,280,000 | -9,195,000 | -6,895,000 |
| yoy | 186.26% | 110.56% | 70.11% | -116.58% | -1318.18% | -562.71% | -159.99% | 242.34% | -91.31% | -75.04% | -46.95% | -42.71% | 8.01% | 33.41% | 100.73% | 154.76% | 25.55% | -10.56% | -31.23% | -38.55% | -7.59% | 28.38% | ||||
| qoq | 35.92% | 274.54% | 62.64% | -65.43% | -0.02% | 202.58% | -115.86% | 2439.66% | -62.03% | -60.77% | -9.51% | -35.55% | 9.10% | -16.62% | -2.27% | 21.50% | 34.75% | 25.45% | 24.04% | -40.12% | -4.01% | -3.54% | 10.83% | -9.95% | 33.36% | |
| net income margin % | 22.18% | 17.89% | 5.64% | 3.88% | 10.67% | 12.59% | 4.97% | -38.27% | -1.91% | -6.34% | -21.42% | -28.91% | -56.15% | -66.51% | -131.03% | -241.38% | -130.56% | -112.25% | -82.75% | -71.75% | -250.58% | -117.56% | -151.51% | -114.92% | -162.28% | -147.46% |
| net income per share | 0.12 | -0.78 | -0.03 | -0.08 | -0.2 | -0.25 | -0.41 | -0.38 | -0.46 | -0.47 | -0.39 | -0.29 | -0.22 | -0.19 | -0.36 | -0.42 | -0.31 | -0.39 | -0.7 | -4.86 | ||||||
| basic | 1.03 | 0.76 | 0.21 | 0.13 | 0.37 | 0.37 | ||||||||||||||||||||
| diluted | 0.92 | 0.7 | 0.2 | 0.12 | 0.35 | 0.35 | ||||||||||||||||||||
| weighted-average common shares outstanding: | ||||||||||||||||||||||||||
| basic | 33,912,669 | 33,721,603 | 33,229,953 | 33,441,394 | 33,119,514 | 32,760,190 | ||||||||||||||||||||
| diluted | 40,558,953 | 39,914,487 | 35,216,837 | 35,683,952 | 35,288,308 | 34,678,895 | ||||||||||||||||||||
| acquired in-process research and development expenses | 27,212,000 | |||||||||||||||||||||||||
| other income | 4,865,000 | 4,996,000 | 2,431,000 | 555,000 | 1,085,000 | -1,076,000 | -784,000 | -227,000 | -345,000 | -249,000 | 171,000 | -454,000 | 566,000 | 499,000 | 371,000 | 217,000 | 590,000 | 56,000 | 247,000 | -103,000 | ||||||
| net income per share | 0.12 | -0.78 | -0.03 | -0.08 | -0.2 | -0.25 | -0.41 | -0.38 | -0.46 | -0.47 | -0.39 | -0.29 | -0.22 | -0.19 | -0.36 | -0.42 | -0.31 | -0.39 | -0.7 | -4.86 | ||||||
| weighted-average common shares outstanding, basic and diluted | 32,517,372 | 32,614,059 | 32,545,352 | 32,260,267 | 29,556,633 | 30,229,936 | 27,983,629 | 27,950,330 | 27,616,839 | 27,701,252 | 27,620,764 | 27,368,090 | 24,702,764 | 27,156,135 | 23,330,918 | 21,221,385 | 14,204,787 | 21,131,618 | 13,133,834 | 1,418,353 | ||||||
| change in fair value of preferred stock warrant liability | -614,000 | 273,000 |
We provide you with 20 years income statements for TransMedics Group stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TransMedics Group stock. Explore the full financial landscape of TransMedics Group stock with our expertly curated income statements.
The information provided in this report about TransMedics Group stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.